-
Raising awareness of the ways in which prostate cancer can affect the sexual minority and gender minority communities.
Access to HealthcareCancerOncologySocial CommitmentTargeted Therapy -
Basel, November 08, 2021 — Novartis, a leader in rheumatology and immuno-dermatology, today announced new analyses from the two-year positive Phase III JUNIPERA study, which demonstrated the treatment response of Cosentyx® (secukinumab) in children and adolescents with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) –…Targeted TherapyReimagine MedicineChronic Illness
-
Basel, September 29, 2021 — Novartis, a leader in immuno-dermatology and rheumatology, today announced new analysis from a Phase IIb study demonstrating the importance of achieving complete control of chronic spontaneous urticaria (CSU) symptoms in improving overall health-related quality of life (HRQoL) for patients1. Complete control of symptoms…Targeted TherapyReimagine MedicineMedical Innovations
-
Basel, September 29, 2021 — Novartis, a leader in immuno-dermatology and rheumatology, today announced data from an international Phase IIIb study, which showed treatment with Cosentyx® (secukinumab) 300 mg in a 2 mL autoinjector (UnoReady® pen) resulted in high efficacy and convenient administration in adults with moderate to severe plaque…Targeted TherapyReimagine MedicineMedical Innovations
-
Basel, September 30, 2021 — Novartis today announced positive Phase IIb data showing remibrutinib (LOU064), a potentially best-in-class oral BTK inhibitor, demonstrated rapid and effective disease control in patients with inadequately controlled chronic spontaneous urticaria (CSU). The data were presented as a late-breaking abstract at the …Targeted TherapyReimagine MedicineMedical Innovations
-
Basel, December 9, 2019 – Novartis today announced results from two analyses of real-world experience with Kymriah® (tisagenlecleucel), the only CAR-T cell therapy approved in two distinct indications. These analyses are from a readout of a 15-year post-marketing study that add to and complement the rigor of the Kymriah pivotal trials with…Targeted TherapyReimagine MedicineCell and Gene TherapyCancer
-
Basel, January 6, 2020 — Novartis AG (NYSE: NVS) (“Novartis”) today announced the successful completion of the previously announced tender offer by its indirect wholly-owned subsidiary, Medusa Merger Corporation (“Purchaser”), for all of the outstanding shares of common stock, par value USD 0.001 per share, of The Medicines Company (NASDAQ: MDCO…Targeted TherapyInnovationHeart FailureChronic IllnessAd Hoc
-
Basel, January 6, 2020 — Novartis AG (NYSE: NVS) (“Novartis”) today announced that it has completed the acquisition of The Medicines Company (the “Company”) through the consummation of a merger of its indirect wholly-owned subsidiary, Medusa Merger Corporation (“Purchaser”), with and into the Company, with the Company surviving the merger, without…Targeted TherapyInnovationHeart FailureChronic Illness
-
Learn about the role of precision oncology in advanced melanoma treatment.
CancerDisease AwarenessLiving With DiseaseOncologyPatient EducationTargeted TherapyGene Testing -
Meet Melanoma survivor TJ Sharpe in the first installment of his new blog series on Novartis.com.
CancerOncologyPatient VoicesSocial CommitmentTargeted TherapyClinical Trials -
With extensive experience in public health management, having worked for the International Red Cross, among others, and as a doctor in emergency situations on the ground in Africa and Asia— Ann Aerts discusses the Novartis Foundation's new leprosy strategy.
Novartis AccessPatient EducationTargeted Therapy -
Advanced Accelerator Applications is working on marrying targeted drug design with nuclear medicine technology to develop drugs that can recognize and treat diseases.
CancerOncologyTargeted TherapyDrug DevelopmentDrug Design
Pagination
- 1
- 2
- › Next page